Literature DB >> 22367373

UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.

Nancy Hakooz1, Sameh Alzubiedi, Al-Motassem Yousef, Tawfiq Arafat, Rana Dajani, Nidaa Ababneh, Said Ismail.   

Abstract

Glucuronidation is one of the most important phase II metabolic pathways. It is catalyzed by a family of UDP-glucuronosyltransferase enzymes (UGTs). One of the subfamilies is UGT1A. Allele frequencies in UGT1A4 differ among ethnic groups. The aim of this study was to determine the allelic frequency of two most common defective alleles: UGT1A4*2 and UGT1A4*3 in a Jordanian population. A total of 216 healthy Jordanian Volunteers (165 males and 51 females) were included in this study. Genotyping for UGT1A4*1, UGT1A4*2 and UGT1A4*3 was done using a well established polymerase chain reaction-restriction fragment length polymorphism test. Among 216 random individuals studied for UGT1A4*2 mutation there were 26 individuals who were heterozygous, giving a prevalence of 12% and an allele frequency of 6.5%. Only one individual was homozygous for UGT1A4*2. The UGT1A4*3 mutation was detected as heterozygous in 9 of 216 individuals indicating a prevalence of 4.2% and allele frequency of 3.5%. Three individuals were homozygous for the UGT1A4*3 indicating a prevalence of 1.4%. The prevalence of UGT1A4*2 is similar to the Caucasians but different from other populations whilst the UGT1A4*3 prevalence in the Jordanian population is distinct from other populations. Our results provide useful information for the Jordanian population and for future genotyping of Arab populations in general.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367373     DOI: 10.1007/s11033-012-1615-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

Review 1.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes.

Authors:  Doris Wiener; Jia-Long Fang; Nicole Dossett; Philip Lazarus
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

3.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

4.  Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.

Authors:  Imad Zalloum; Nancy Hakooz; Tawfiq Arafat
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

5.  Prevalence of CYP2C19 polymorphisms in the Lebanese population.

Authors:  Isabelle Djaffar Jureidini; Nabil Chamseddine; Sose Keleshian; Rania Naoufal; Laila Zahed; Noha Hakime
Journal:  Mol Biol Rep       Date:  2011-03-05       Impact factor: 2.316

6.  UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation.

Authors:  Asami Mori; Yoshihiro Maruo; Masaru Iwai; Hiroshi Sato; Yoshihiro Takeuchi
Journal:  Drug Metab Dispos       Date:  2005-02-11       Impact factor: 3.922

Review 7.  Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract.

Authors:  R H Tukey; C P Strassburg
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

8.  Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.

Authors:  Kenichiro Ogura; Yuko Ishikawa; Teppei Kaku; Takahito Nishiyama; Tomokazu Ohnuma; Kei Muro; Akira Hiratsuka
Journal:  Biochem Pharmacol       Date:  2006-02-14       Impact factor: 5.858

9.  CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population.

Authors:  Fatma B'chir; Sofia Pavanello; Jalel Knani; Sami Boughattas; Maurice J Arnaud; Saâd Saguem
Journal:  Life Sci       Date:  2009-03-28       Impact factor: 5.037

10.  Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

Authors:  Dongxiao Sun; Gang Chen; Ryan W Dellinger; Kimberly Duncan; Jia-Long Fang; Philip Lazarus
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

View more
  10 in total

1.  Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.

Authors:  Marisol López; Pedro Dorado; Alberto Ortega; Eva Peñas-Lledó; Nancy Monroy; Irma Silva-Zolezzi; Jesús Cobaleda; Alicia Gallego-Aguilera; María Elisa Alonso; Adrián Llerena
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

2.  The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.

Authors:  Hyeon Jeong Suh; Seo Hyun Yoon; Kyung-Sang Yu; Joo-Youn Cho; Sang-In Park; Eunyoung Lee; Jeong-Ok Lee; Youngil Koh; Kyoung-Ho Song; Pyoeng Gyun Choe; Eu Suk Kim; Soo-Mee Bang; Hong Bin Kim; Inho Kim; Nam Joong Kim; Sang Hoon Song; Wan Beom Park; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers.

Authors:  Hartley C Atkinson; Ioana Stanescu; Isam I Salem; Amanda L Potts; Brian J Anderson
Journal:  Eur J Clin Pharmacol       Date:  2014-12-06       Impact factor: 2.953

4.  Analysis of Comprehensive Pharmacogenomic Profiling of VIP Variants Among the Genetically Isolated Chechen Subpopulation from Jordan.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Nancy M Hakooz; Mansour A Alghamdi; Rana B Dajani
Journal:  Pharmgenomics Pers Med       Date:  2020-07-14

5.  Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.

Authors:  Limin Liu; Limei Zhao; Qiuning Wang; Feng Qiu; Xiujun Wu; Yanan Ma
Journal:  Eur J Clin Pharmacol       Date:  2015-08-26       Impact factor: 2.953

6.  Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China.

Authors:  Ying Chang; Li-ya Yang; Meng-Chao Zhang; Song-Yan Liu
Journal:  Eur J Clin Pharmacol       Date:  2014-05-13       Impact factor: 2.953

7.  Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.

Authors:  Shansen Xu; Limin Liu; Yanan Chen; Mei Liu; Tong Lu; Huanxin Wang; Shihao Liu; Mingming Zhao; Limei Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-01-16       Impact factor: 2.953

8.  Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?

Authors:  Alessio Provenzani; Manuela Labbozzetta; Monica Notarbartolo; Paola Poma; Piera Polidori; Giovanni Vizzini; Natale D'Alessandro
Journal:  Int J Clin Pharm       Date:  2015-07-15

Review 9.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

Review 10.  Interpatient variability in dexmedetomidine response: a survey of the literature.

Authors:  Samantha F Holliday; Sandra L Kane-Gill; Philip E Empey; Mitchell S Buckley; Pamela L Smithburger
Journal:  ScientificWorldJournal       Date:  2014-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.